免疫组库测序市场
免疫组库测序市场：2026年市场规模约为3.5841亿美元，2031年市场规模约为5.6036亿美元；预测期复合年增长率为9.35%；当前最大市场为北美；增长最快的市场为亚太地区。
市场研究正文
规模、增长、细分、驱动因素与关键问题
当前质量分 100.00，审核状态 accepted。结构化字段已按 RoboInd 内容层级组织。
核心结论
免疫组库测序市场：2026年市场规模约为3.5841亿美元，2031年市场规模约为5.6036亿美元；预测期复合年增长率为9.35%；当前最大市场为北美；增长最快的市场为亚太地区。
市场走势
结构化指标
| 指标 | 年份 | 数值 | 性质 |
|---|---|---|---|
| 复合年增长率 | 2031 | 9.35% | 机构预测 |
| 市场规模 | 2026 | USD 358.41 million | 机构预测 |
| 市场规模 | 2031 | USD 560.36 million | 机构预测 |
细分市场份额
市场结构
| 维度 | 细分项 | 年份 | 份额 |
|---|---|---|---|
| application | oncology and cancer immunotherapy | 2025 | 32.440% |
| end_user | pharmaceutical and biotechnology companies | 2025 | 38.670% |
| geography | North America | 2025 | 39.470% |
| receptor_type | T-cell receptor sequencing | 2025 | 62.590% |
| technology | sequencing technologies | 2025 | 53.250% |
关键结论
- application 维度中，oncology and cancer immunotherapy 在 2025 年的公开份额为 32.44%。
- end_user 维度中，pharmaceutical and biotechnology companies 在 2025 年的公开份额为 38.67%。
- geography 维度中，North America 在 2025 年的公开份额为 39.47%。
- receptor_type 维度中，T-cell receptor sequencing 在 2025 年的公开份额为 62.59%。
- technology 维度中，sequencing technologies 在 2025 年的公开份额为 53.25%。
主要参与者
- 10x Genomics, Inc.
- Agilent Technologies, Inc.
- BGI Group
- CD Genomics
- F. Hoffmann-La Roche Ltd
增长驱动因素
| 因素 | 影响 CAGR | 地区相关性 | 影响周期 |
|---|---|---|---|
| Precision Immuno-Oncology and Cell Therapy Programs | +2.500% | Global, concentrated in North America and EU | Short term (≤ 2 years) |
| Vaccine and Infectious Disease Repertoire Studies | +1.600% | Global, with strong traction in North America, EU, and APAC | Medium term (2-4 years) |
| NGS Immune Profiling in Autoimmune Research | +1.400% | North America and EU core, with spillover to APAC | Medium term (2-4 years) |
| Longitudinal Monitoring in Transplantation and MRD | +1.000% | North America and EU, with APAC emerging | Short term (≤ 2 years) |
| Paired-Chain and Full-Length Receptor Discovery | +0.800% | North America, EU, South Korea, and Japan | Medium term (2-4 years) |
| AIRR Datasets for AI-Assisted Discovery | +0.600% | Global, led by North America and EU research consortia | Long term (≥ 4 years) |
市场制约因素
| 因素 | 影响 CAGR | 地区相关性 | 影响周期 |
|---|---|---|---|
| Capital Intensity and Specialized Bioinformatics Needs | -1.300% | Global, most pronounced in APAC emerging markets and South America | Long term (≥ 4 years) |
| Clinical Validation and Reimbursement Limits | -0.600% | Global, most acute in EU, APAC, and emerging markets | Medium term (2-4 years) |
| Loss of Chain Pairing and Tissue Context in Bulk Assays | -0.400% | Global | Short term (≤ 2 years) |
| Privacy, Cross-Border Governance, and Interoperability Friction | -0.400% | EU and regions with GDPR-equivalent frameworks, and APAC | Medium term (2-4 years) |
报告关注的关键问题
What is driving demand for immune repertoire sequencing?
Use is expanding in immuno-oncology biomarkers, cell therapy research, vaccine studies, autoimmune research, transplantation monitoring, and minimal residual disease testing.
How large is the immune repertoire sequencing market?
The market is estimated at USD 358.41 million in 2026 and is forecast to reach USD 560.36 million by 2031, at a 9.35% CAGR.
Which product category has the largest revenue base?
Assay kits and reagents led with 57.62% revenue share in 2025 because every sequencing run requires new consumables.
Which application is expected to grow fastest?
Infectious diseases and vaccine development is forecast to grow at an 11.46% CAGR through 2031.
Why is North America the leading region?
North America held 39.47% revenue share in 2025, supported by clinical diagnostics, pharmaceutical research, academic centers, and established reimbursement for clonoSEQ.
What limits clinical deployment of AIRR-seq tests?
Capital requirements, specialist bioinformatics needs, clinical validation, reimbursement gaps, and data governance requirements constrain broader clinical adoption.
市场概览
- 增长最快市场：亚太地区
- 最大市场：北美
- 市场集中度：中等
查看来源：Mordor Intelligence